Stattic
Based on 282 publication(s) in Google Scholar
Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.58%
- CAS No.: 19983-44-9
- Formule: C8H5NO4S
- Masse moléculaire:211.19
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Stattic
More- Mol Cancer. 2019 Mar 30;18(1):64. [Abstract]
- Cell Metab. 2019 Jan 8;29(1):141-155.e9. [Abstract]
- Nat Immunol. 2025 Sep;26(9):1567-1580. [Abstract]
- Gut. 2020 Jan;69(1):122-132. [Abstract]
- Drug Resist Updat. 2025 Jul:81:101224. [Abstract]
- Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
- Cell Mol Immunol. 2025 Oct 14. [Abstract]
- Nat Cell Biol. 2026 Mar 13. [Abstract]
- Cell Host Microbe. 2026 Feb 11;34(2):245-262.e8. [Abstract]
- Cancer Res. 2024 Feb 1;84(3):479-492. [Abstract]
- Nat Commun. 2026 Apr 14;17(1):4194. [Abstract]
- Nat Commun. 2025 Sep 25;16(1):8409. [Abstract]
- Nat Commun. 2025 Mar 27;16(1):3012. [Abstract]
- Nat Commun. 2025 Jan 3;16(1):289. [Abstract]
- Nat Commun. 2021 Jun 15;12(1):3651. [Abstract]
- Cell Death Differ. 2025 Nov 11. [Abstract]
- Cell Death Differ. 2025 Jul 19. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6430-6443. [Abstract]
- Acta Pharm Sin B. 2025 Aug;15(8):4078-4095. [Abstract]
- Acta Pharm Sin B. 2025 Mar;15(3):1535-1551. [Abstract]
- Acta Pharm Sin B. 2025 Jan;15(1):409-423. [Abstract]
- Sci Transl Med. 2021 Oct 6;13(614):eabg6428. [Abstract]
- Adv Sci (Weinh). 2023 Dec;10(35):e2305080. [Abstract]
- J Clin Invest. 2022 Oct 17;132(20):e157917. [Abstract]
- Exp Hematol Oncol. 2024 Oct 1;13(1):97. [Abstract]
- Exp Hematol Oncol. 2024 Jun 26;13(1):63. [Abstract]
- Theranostics. 2024 Oct 7;14(17):6543-6559. [Abstract]
- Theranostics. 2023 Apr 23;13(8):2588-2604. [Abstract]
- Theranostics. 2023 Apr 17;13(7):2263-2280. [Abstract]
- J Adv Res. 2025 Nov 29:S2090-1232(25)00961-0. [Abstract]
- J Adv Res. 2024 Feb:56:1-14. [Abstract]
- J Adv Res. 2023 May:47:151-162. [Abstract]
- J Exp Clin Cancer Res. 2025 Jun 5;44(1):172. [Abstract]
- J Exp Clin Cancer Res. 2025 Jan 31;44(1):33. [Abstract]
- J Exp Clin Cancer Res. 2024 Oct 3;43(1):277. [Abstract]
- J Exp Clin Cancer Res. 2023 Aug 11;42(1):206. [Abstract]
- J Exp Clin Cancer Res. 2021 Jan 4;40(1):4. [Abstract]
- J Exp Clin Cancer Res. 2018 Dec 20;37(1):321. [Abstract]
- J Exp Clin Cancer Res. 2018 Jul 3;37(1):133. [Abstract]
- J Nanobiotechnology. 2025 Apr 15;23(1):291. [Abstract]
- Sci Adv. 2025 Jun 27;11(26):eadu8422. [Abstract]
- Sci Adv. 2022 Feb 11;8(6):eabj1262. [Abstract]
- Redox Biol. 2025 Apr:81:103557. [Abstract]
- Redox Biol. 2023 Jun:62:102702. [Abstract]
- Redox Biol. 2021 Oct;46:102098. [Abstract]
- Cell Rep Med. 2026 Apr 21;7(4):102691. [Abstract]
- Cell Rep Med. 2024 Mar 19;5(3):101472. [Abstract]
- J Immunother Cancer. 2020 Mar;8(1):e000111. [Abstract]
- J Immunother Cancer. 2019 Jul 12;7(1):178. [Abstract]
- J Immunother Cancer. 2018 Dec 18;6(1):151. [Abstract]
- Pharmacol Res. 2022 Jun;180:106227. [Abstract]
- Pharmacol Res. 2019 Sep:147:104307. [Abstract]
- Cell Mol Biol Lett. 2025 Nov 28;30(1):141. [Abstract]
- J Neuroinflammation. 2025 Mar 15;22(1):83. [Abstract]
- J Neuroinflammation. 2024 Sep 16;21(1):227. [Abstract]
- Cancer Lett. 2024 May 10:216956. [Abstract]
- J Neuroinflammation. 2022 Feb 18;19(1):52. [Abstract]
- Cancer Lett. 2021 Oct 10:518:35-48. [Abstract]
- Int J Biol Sci. 2023 Jan 1;19(2):465-483. [Abstract]
- Cell Death Dis. 2026 Mar 27;17(1):364. [Abstract]
- Cell Death Dis. 2025 Feb 25;16(1):129. [Abstract]
- Cell Death Dis. 2025 Jan 20;16(1):31. [Abstract]
- Cell Death Dis. 2024 Jun 19;15(6):430. [Abstract]
- Cell Death Dis. 2023 Aug 25;14(8):557. [Abstract]
- Cell Death Dis. 2022 May 25;13(5):496. [Abstract]
- Cell Death Dis. 2022 Jan 10;13(1):36. [Abstract]
- Cell Death Dis. 2021 Sep 28;12(10):886. [Abstract]
- Cell Death Dis. 2021 Oct 5;12(10):910. [Abstract]
- Cell Death Dis. 2019 Oct 14;10(10):781. [Abstract]
- Cell Death Dis. 2018 Jan 18;9(2):25. [Abstract]
- Genes Dis. 2026 Feb 14.
- Osteoarthritis Cartilage. 2025 May;33(5):574-589. [Abstract]
- Cell Commun Signal. 2025 Oct 10;23(1):431. [Abstract]
- Cell Commun Signal. 2024 Jun 6;22(1):313. [Abstract]
- Cell Commun Signal. 2024 Jun 18;22(1):335. [Abstract]
- Int J Biol Macromol. 2025 Dec 3;337(Pt 1):149451. [Abstract]
- Int J Biol Macromol. 2024 Jun;269(Pt 2):131964. [Abstract]
- Acta Pharmacol Sin. 2025 Jan;46(1):184-195. [Abstract]
- Phytomedicine. 2026 Apr:153:157988. [Abstract]
- Phytomedicine. 2025 Oct 4:148:157371. [Abstract]
- Phytomedicine. 2025 Sep 15:148:157263. [Abstract]
- Phytomedicine. 2024 Dec:135:156095. [Abstract]
- Phytomedicine. 2024 Jul 25:130:155482. [Abstract]
- Phytomedicine. 2024 Jun:128:155333. [Abstract]
- Phytomedicine. 2022 Oct:105:154385. [Abstract]
- Phytomedicine. 2022 May:99:154030. [Abstract]
- Phytomedicine. 2020 Apr;69:153194. [Abstract]
- Free Radic Biol Med. 2024 Sep 11:S0891-5849(24)00657-9. [Abstract]
- Free Radic Biol Med. 2023 Aug 20:205:163-174. [Abstract]
- Free Radic Biol Med. 2023 May 20:201:111-125. [Abstract]
- Mater Today Nano. 9 November 2021, 100155.
- Am J Transplant. 2020 Dec;20(12):3354-3366. [Abstract]
- NPJ Precis Oncol. 2025 May 16;9(1):143. [Abstract]
- Br J Pharmacol. 2019 Jun;176(11):1717-1727. [Abstract]
- JHEP Rep. 2025 Jan 20;7(5):101329. [Abstract]
- Biomed Pharmacother. 2025 Apr 16:187:118054. [Abstract]
- J Transl Med. 2025 Feb 24;23(1):224. [Abstract]
- J Transl Med. 2022 May 31;20(1):248. [Abstract]
- Biomed Pharmacother. 2022 May:149:112733. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2019;7(2):255-274. [Abstract]
- Stem Cell Res Ther. 2025 May 5;16(1):227. [Abstract]
- Stem Cell Res Ther. 2025 Feb 4;16(1):40. [Abstract]
- Environ Pollut. 2025 Jan 1:125627. [Abstract]
- Stem Cell Res Ther. 2024 Sep 11;15(1):292. [Abstract]
- Oncogene. 2022 Nov;41(46):4983-4993. [Abstract]
- Oncogene. 2022 Feb;41(6):907-919. [Abstract]
- Aging Cell. 2024 Aug 15:e14305. [Abstract]
- Cell Death Discov. 2025 Jun 6;11(1):268. [Abstract]
- Cell Death Discov. 2025 Apr 8;11(1):156. [Abstract]
- Cell Death Discov. 2024 Apr 1;10(1):159. [Abstract]
- Cell Rep. 2024 Dec 13;43(12):115057. [Abstract]
- Br J Cancer. 2021 Jul;125(1):101-111. [Abstract]
- Int J Nanomedicine. 2022 Jan 11;17:137-150. [Abstract]
- Cell Mol Life Sci. 2025 Nov 13;82(1):396. [Abstract]
- J Agric Food Chem. 2025 Aug 27;73(34):21566-21577. [Abstract]
- Cell Mol Life Sci. 2025 Feb 22;82(1):85. [Abstract]
- EMBO Rep. 2023 Jan 9;24(1):e54729. [Abstract]
- Ecotoxicol Environ Saf. 2022 Dec 15:248:114268. [Abstract]
- Mol Ther Nucleic Acids. 2022 Feb 20:28:35-46. [Abstract]
- Cancer Cell Int. 2023 Dec 16;23(1):323. [Abstract]
- Cancer Cell Int. 2023 Oct 11;23(1):237. [Abstract]
- Cancer Cell Int. 2022 Jan 15;22(1):24. [Abstract]
- Food Biosci. 2025 Jun.
- J Mol Cell Biol. 2023 Aug 3;15(4):mjad025. [Abstract]
- Cell Biol Toxicol. 2023 Aug;39(4):1835-1850. [Abstract]
- Biochem Pharmacol. 2025 Dec 10:245:117629. [Abstract]
- Biochem Pharmacol. 2025 Apr 29:116963. [Abstract]
- J Ginseng Res. 2024 Jul;48(4):405-416. [Abstract]
- Cell Prolif. 2023 Jan;56(1):e13337. [Abstract]
- J Ethnopharmacol. 2026 May 10:362:121296. [Abstract]
- J Ethnopharmacol. 2026 Apr 24:361:121268. [Abstract]
- J Ethnopharmacol. 2024 May 13:118329. [Abstract]
- J Ethnopharmacol. 2024 Aug 10:330:118196. [Abstract]
- Mol Ther Oncolytics. 2022 Jun 25;26:175-188. [Abstract]
- Life Sci. 2025 May 21:375:123744. [Abstract]
- Life Sci. 2024 Aug 13:122968. [Abstract]
- Bone Joint Res. 2024 Apr 4;13(4):157-168. [Abstract]
- Commun Biol. 2022 Dec 1;5(1):1316. [Abstract]
- Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]
- Respir Res. 2023 Oct 28;24(1):260. [Abstract]
- Inflammation. 2024 Feb;47(1):307-322. [Abstract]
- Nutrients. 2019 Apr 5;11(4):791. [Abstract]
- Int J Oncol. 2026 May;68(5):59. [Abstract]
- PLoS Pathog. 2026 Mar 11;22(3):e1014053. [Abstract]
- Int J Mol Sci. 2024 Aug 19;25(16):9007. [Abstract]
- Int J Mol Sci. 2024 Jul 26;25(15):8142. [Abstract]
- Int J Mol Sci. 2023 Apr 13;24(8):7219. [Abstract]
- Int J Oncol. 2023 Mar;62(3):42. [Abstract]
- J Drug Deliv Sci Technol. 2020 Jul.
- Biomolecules. 2024 Jun 8;14(6):671. [Abstract]
- Front Pharmacol. 2022 Mar 17;13:807440. [Abstract]
- Eur J Pharm Sci. 2026 Mar 1:218:107429. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 2):115861. [Abstract]
- Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):68. [Abstract]
- Int Immunopharmacol. 2025 May 6:157:114731. [Abstract]
- Int Immunopharmacol. 2025 May 26:159:114947. [Abstract]
- Eur J Pharmacol. 2025 Apr 9:177606. [Abstract]
- Int Immunopharmacol. 2025 Jan 6:147:113948. [Abstract]
- Int Immunopharmacol. 2024 Sep 27;142(Pt B):113258. [Abstract]
- Int Immunopharmacol. 2024 Feb 15:128:111500. [Abstract]
- Int Immunopharmacol. 2024 Jan 25:127:111367. [Abstract]
- Am J Physiol Cell Physiol. 2024 Feb 1;326(2):C400-C413. [Abstract]
- Int Immunopharmacol. 2023 Oct:123:110709. [Abstract]
- Int Immunopharmacol. 2023 Jun:119:110216. [Abstract]
- Mol Cancer Res. 2021 Sep;19(9):1534-1545. [Abstract]
- Int Immunopharmacol. 2021 Jul:96:107587. [Abstract]
- Int Immunopharmacol. 2020 Apr;81:106240. [Abstract]
- Mol Cancer Res. 2019 Jun;17(6):1378-1390. [Abstract]
- Toxicology. 2026 Jun:523:154449. [Abstract]
- Cancer Biol Ther. 2023 Dec 31;24(1):2226418. [Abstract]
- Neuropharmacology. 2023 Sep 1:235:109571. [Abstract]
- J Mol Biol. 2020 Sep 1;12(9):723-737. [Abstract]
- Cancers (Basel). 2022 Jun 8;14(12):2845. [Abstract]
- J Integr Agric. 10 May 2022.
- Mediators Inflamm. 2025 Nov 12:2025:8862449. [Abstract]
- J Mol Med (Berl). 2025 Oct 15. [Abstract]
- FASEB J. 2024 Sep 30;38(18):e70062. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Aug;1870(6):167216. [Abstract]
- J Cell Mol Med. 2022 Apr;26(8):2363-2376. [Abstract]
- J Cell Mol Med. 2019 Apr;23(4):2970-2983. [Abstract]
- Oncol Res. 2026 Jan 19;34(2):25. [Abstract]
- J Inflamm Res. 2025 Sep 8:18:12361-12377. [Abstract]
- J Inflamm (Lond). 2025 Jun 11;22(1):21. [Abstract]
- Oncol Res. 2024 Mar 20;32(4):625-641. [Abstract]
- iScience. 2024 Feb 9;27(3):109160. [Abstract]
- J Inflamm Res. 2022 May 31:15:3187-3205. [Abstract]
- Am J Physiol Heart Circ Physiol. 2022 Jul 1;323(1):H103-H120. [Abstract]
- J Funct Foods. 2025 Apr.
- Antiviral Res. 2023 Sep:217:105676. [Abstract]
- Sci Rep. 2025 Sep 29;15(1):33534. [Abstract]
- Sci Rep. 2025 Aug 14;15(1):29900. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):21259. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):22204. [Abstract]
- J Biol Chem. 2024 Jun 27:107499. [Abstract]
- Biomedicines. 2023 Dec 1;11(12):3194. [Abstract]
- Oncol Rep. 2019 Jun;41(6):3219-3232. [Abstract]
- Cell Signal. 2025 May 17:111877. [Abstract]
- Cell Signal. 2025 Jan 23:127:111617. [Abstract]
- ACS Pharmacol Transl Sci. 2023 Dec 5;7(1):176-185. [Abstract]
- Cell Signal. 2023 Aug:108:110717. [Abstract]
- Cytokine. 2023 Mar:163:156120. [Abstract]
- Cell Signal. 2022 Apr:92:110265. [Abstract]
- Cell Signal. 2019 Mar:55:65-72. [Abstract]
- World J Stem Cells. 2024 Nov 26;16(11):906-925. [Abstract]
- Clin Exp Med. 2026 Jan 2;26(1):68. [Abstract]
- Vet Res. 2025 Dec 16;56(1):229. [Abstract]
- Viruses. 2026 Jan 1.
- Metab Brain Dis. 2025 Jul 1;40(6):238. [Abstract]
- Mol Med Rep. 2025 Feb;31(2):51. [Abstract]
- Vet Res. 2023 Oct 2;54(1):86. [Abstract]
- Vascul Pharmacol. 2023 Dec:153:107233. [Abstract]
- Exp Cell Res. 2023 Mar 22;426(2):113565. [Abstract]
- Mol Med Rep. 2023 Apr;27(4):81. [Abstract]
- Parasit Vectors. 2022 May 3;15(1):157. [Abstract]
- Front Physiol. 2022 Jan 5:12:736920. [Abstract]
- Front Physiol. 2021 Aug 18;12:724470. [Abstract]
- Front Oncol. 2021 Nov 22;11:762523. [Abstract]
- J Cancer. 2024 Aug 19;15(16):5415-5424. [Abstract]
- Mol Carcinog. 2024 Sep;63(9):1738-1749. [Abstract]
- J Cancer. 2021 Jun 11;12(16):4819-4829. [Abstract]
- J Cancer. 2020 Jan 20;11(7):1859-1868. [Abstract]
- IUBMB Life. 2018 Jan;70(1):81-91. [Abstract]
- Mol Carcinog. 2017 Nov;56(11):2434-2445. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Dec 11. [Abstract]
- Immunol Res. 2025 Jun 26;73(1):99. [Abstract]
- Immunol Res. 2025 Feb 11;73(1):49. [Abstract]
- Biochim Biophys Acta Gene Regul Mech. 2019 Aug;1862(8):796-806. [Abstract]
- Med Microbiol Immunol. 2025 Nov 14;214(1):50. [Abstract]
- Mol Immunol. 2025 May:181:9-17. [Abstract]
- Arch Biochem Biophys. 2024 Nov:761:110170. [Abstract]
- Int J Hyperthermia. 2024 Feb 13;41(1):2310017. [Abstract]
- J Bioenerg Biomembr. 2023 Oct;55(5):325-339. [Abstract]
- Toxicol Lett. 2025 Dec 30:416:111811. [Abstract]
- Discov Oncol. 2025 May 12;16(1):739. [Abstract]
- Discov Oncol. 2025 Apr 29;16(1):637. [Abstract]
- Toxicol Lett. 2024 Apr:394:102-113. [Abstract]
- Immunol Lett. 2026 Apr:278:107122. [Abstract]
- Brain Sci. 2025 Jan 28;15(2):128. [Abstract]
- Int J Biochem Cell Biol. 2025 Feb 1:180:106750. [Abstract]
- Vet Microbiol. 2025 Dec:311:110733. [Abstract]
- Int J Immunopathol Pharmacol. 2024 Jan-Dec:38:3946320241249445. [Abstract]
- DNA Cell Biol. 2022 Aug;41(8):778-787. [Abstract]
- Cancer Manag Res. 2021 May 7:13:3685-3697. [Abstract]
- Tissue Cell. 2025 Jul 29:97:103065. [Abstract]
- Theriogenology. 2024 Mar 1:216:118-126. [Abstract]
- Gene. 2026 May 15:991:150084. [Abstract]
- J Chin Med Assoc. 2025 Jul 22. [Abstract]
- Dev Comp Immunol. 2025 Jan 25:105325. [Abstract]
- Odontology. 2025 Jul;113(3):1081-1091. [Abstract]
- J Oral Biosci. 2025 Dec;67(4):100707. [Abstract]
- Immunobiology. 2025 Apr 21;230(3):152902. [Abstract]
- Eur J Haematol. 2023 Apr;110(4):435-443. [Abstract]
- Immunobiology. 2022 Jan;227(1):152165. [Abstract]
- Exp Ther Med. 2020 Sep;20(3):2148-2156. [Abstract]
- Exp Ther Med. 2020 Feb;19(2):1297-1303. [Abstract]
- Leuk Lymphoma. 2023 Jan;64(1):71-78. [Abstract]
- Biochem Biophys Res Commun. 2019 Jul 23;515(2):394-400. [Abstract]
- FASEB Bioadv. 2025 Jan 7;7(2):e1488. [Abstract]
- Int J Rheum Dis. 2024 May;27(5):e15164. [Abstract]
- In Vitro Cell Dev Biol Anim. 2025 Aug;61(7):886-897. [Abstract]
- Curr Med Sci. 2025 Jun;45(3):626-639. [Abstract]
- Turk J Haematol. 2025 May 22;42(2):82-91. [Abstract]
- bioRxiv. 2025 Oct 27.
- SSRN. 2025 Oct 21.
- bioRxiv. 2025 January 31.
- Res Sq. 2024 Jun 27.
- Res Sq. 2024 Jun 05.
- SSRN. 2024 Apr 3.
- SSRN. 2024 Feb 13.
- Research Square Preprint. 2023 Nov 1.
- Research Square Preprint. 2023 Oct 11.
- SSRN. 3 Nov 2022.
- Oxid Med Cell Longev. 2022 May 10;2022:9635075. [Abstract]
- Comput Intell Neurosci. 2022 Apr 22;2022:2685648. [Abstract]
- Int J Biol Sci. 2022 Jan 16;18(4):1363-1380. [Abstract]
- Research Square Preprint. 2021 Nov.
- Research Square Preprint. 2021 Aug.
- Ann Transl Med. 2021 May;9(9):784. [Abstract]
- Research Square Preprint. 2021 Jul.
- Research Square Preprint. 2021 Jul.
- Research Square Preprint. 2020 Dec.
- Research Square Preprint. 2020 Sep.
-
WB
-
Cell Migration/Invasion Assay
-
WB
-
Flow Cytometry
-
Flow Cytometry
Activité biologique
|
STAT3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.5 μM
Compound: Stattic
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26396689] |
| A549 | IC50 |
4.4 μM
Compound: Stattic
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 27718470] |
| ASPC1 | IC50 |
1.32 μM
Compound: Stattic
|
Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
|
[PMID: 24904966] |
| DU-145 | IC50 |
1.84 μM
Compound: 2
|
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
|
[PMID: 37594012] |
| DU-145 | IC50 |
2.5 μM
Compound: Stattic
|
Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26396689] |
| HCT-116 | IC50 |
1.08 μM
Compound: Stattic
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 27718470] |
| HCT-116 | IC50 |
2.16 μM
Compound: Stattic
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31048139] |
| HEL | IC50 |
1.59 μM
Compound: Stattic
|
Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33689932] |
| HepG2 | IC50 |
3.52 μM
Compound: Stattic
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31048139] |
| HepG2 | IC50 |
8.35 μM
Compound: Cpd IV
|
Antitumor activity against human HepG2 cells measured after 48 hrs by MTT assay
Antitumor activity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 37859719] |
| Huh-7 | IC50 |
7.89 μM
Compound: Cpd IV
|
Antitumor activity against human Huh7 cells measured after 48 hrs by MTT assay
Antitumor activity against human Huh7 cells measured after 48 hrs by MTT assay
|
[PMID: 37859719] |
| L02 | IC50 |
5.2 μM
Compound: Stattic
|
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31048139] |
| MCF-10A | IC50 |
6.11 μM
Compound: Stattic
|
Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31048139] |
| MCF7 | IC50 |
1.7 μM
Compound: Stattic
|
Antiproliferative activity against human MCF7 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33689932] |
| MCF7 | IC50 |
2.16 μM
Compound: Stattic
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26396689] |
| MCF7 | IC50 |
2.36 μM
Compound: Stattic
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 27718470] |
| MCF7 | IC50 |
3.6 μM
Compound: Stattic
|
Antiproliferative activity against ER-positive human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
Antiproliferative activity against ER-positive human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
|
[PMID: 24904966] |
| MCF7 | IC50 |
3.71 μM
Compound: Stattic
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31048139] |
| MDA-MB-231 | IC50 |
1.56 μM
Compound: Stattic
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26396689] |
| MDA-MB-231 | IC50 |
1.66 μM
Compound: 2
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
|
[PMID: 37594012] |
| MDA-MB-231 | IC50 |
1.68 μM
Compound: Stattic
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 27718470] |
| MDA-MB-231 | IC50 |
1.81 μM
Compound: Stattic
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31048139] |
| MDA-MB-231 | IC50 |
2.64 μM
Compound: Stattic
|
Antiproliferative activity against human MDA-MB-231 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-231 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
|
[PMID: 32603980] |
| MDA-MB-231 | IC50 |
2.89 μM
Compound: Stattic
|
Antiproliferative activity against ER-negative and triple-negative human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
Antiproliferative activity against ER-negative and triple-negative human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
|
[PMID: 24904966] |
| MDA-MB-435S | IC50 |
1.87 μM
Compound: Stattic
|
Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26396689] |
| MDA-MB-453 | IC50 |
4.4 μM
Compound: Stattic
|
Antiproliferative activity against human MDA-MB-453 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-453 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33689932] |
| MDA-MB-468 | IC50 |
1.92 μM
Compound: Stattic
|
Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay
|
[PMID: 32603980] |
| MDA-MB-468 | IC50 |
1.92 μM
Compound: Stattic
|
Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33689932] |
| NIH3T3 | IC50 |
1.18 μM
Compound: Stattic
|
Antiproliferative activity against mouse NIH3T3 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by CCK-8 assay
Antiproliferative activity against mouse NIH3T3 cells assessed as cell growth inhibition incubated for 24 to 72 hrs by CCK-8 assay
|
[PMID: 36463728] |
| PANC-1 | IC50 |
2.9 μM
Compound: Stattic
|
Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26396689] |
| PANC-1 | IC50 |
3.77 μM
Compound: Stattic
|
Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay
|
[PMID: 24904966] |
| THLE-2 | IC50 |
>100 μM
Compound: Cpd IV
|
Cytotoxicity against THLE-2 cells measured after 48 hrs by MTT assay
Cytotoxicity against THLE-2 cells measured after 48 hrs by MTT assay
|
[PMID: 37859719] |
Stattic (20 μM; 24 hours) inhibits STAT3 phosphorylation (Y705) and selectively inhibits P-STAT3 as demonstrated by the lack of inhibition of P-ERK1/2 in ALDH+ and D44+/CD24+ subpopulations of Panc-1 and HPAC pancreatic cancer cell lines[1].
Stattic (2.5, 5, 10 μM; for 4 h) significantly reduces the nuclear level of pSTAT3 and survivin in PC3M-1E8 cells at 10 μM. Stattic (2.5-10 μM; for 24 h) inhibits IL-6-induced STAT3 activation in a dose-dependent manner[2].
Stattic (2.5, 5, 10 μM; for 48 h) suppresses both the growth and induces apoptosis prostate cancer cells (PC3M-1E8 cells) with 10 μM. Stattic does not induce significant cell apoptosis with 2.5 μM, 5 μM[2].
Stattic (2.5, 5, 10 μM; for 48 h) shows significant S phase accumulation[2].
Stattic can not lead to significant morphological changes or apoptosis and has little STAT3 phosphorylation in A2780 cells and HUVECs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Age-matched wild-type (WT) C57BL/6 mice[3]
-
Dosage:10 mg/kg
-
Administration:IP; three timesper week for 10 week
-
Result:Increased levels of proteinuria, BUN and serum creatinine.
Significantly suppressed the gene expression levels of renal injury markers (Lcn2, Kim-1), pro-inflammatory cytokines (Il-6, KC), pro-fibrotic genes (Tgf-β, Col1a1, α-Sma) and Mmp9.
Chemical Information
-
CAS No. 19983-44-9
-
Appearance Solid
-
Masse moléculaire 211.19
-
Formule C8H5NO4S
-
Color Off-white to yellow
-
SMILES
O=[N+](C1=CC=C(C=CS2(=O)=O)C2=C1)[O-]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (282)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. [Abstract]2019 Mar 30;18(1):64. PMID: 30927925
Stattic purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2019 Mar 30;18(1):64. [Abstract]
Western blot analysis of HCT116 cells alone, IL6-supplemented HCT116, TAMs-co-cultured HCT116 in the presence or absence of Stattic (15 μM).
-
Cell Metab
2019 Jan 8;29(1):141-155.e9. PMID: 30174305 -
Nat Immunol
2025 Sep;26(9):1567-1580. PMID: 40707822 -
Gut
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. [Abstract]2020 Jan;69(1):122-132. PMID: 31076405 -
Drug Resist Updat
DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma. [Abstract]2025 Jul:81:101224. PMID: 40058099 -
Ann Rheum Dis
2024 Aug 20:ard-2024-226067. PMID: 39164066
Stattic purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
Stattic (2.5 µM; 48 h) significantly inhibits IL-9 (100 ng/mL; 48 h)-induced STAT3 phosphorylation and PU.1 expression in RA-Th9 cells.
Stattic purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
Stattic (2.5 µM; 48 h) in Th9 cell supernatant significantly suppresses the migratory ability of RA-FLS.
Stattic purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
Western blot analysis was performed to detect the IL-9 effect on the JAK1/STAT3 pathway in RA-Th9 cells. The cell treated with tofacitinib (10 μM, 48 h), stattic (2.5 μM, 48 h).
Stattic purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
Flow cytometry was used to detect the JAK inhibitor tofacitinib (10 μM, 48 h) effect, STAT3 inhibitor statics (2.5 μM, 48 h), and PU.1 inhibitor DB2313 on the release of IL-9 from Th9 cells.
Stattic purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
Flow cytometry was used to detect IL-9 and JAK inhibitor tofacitinib (10 μM, 48 h) effect, STAT3 inhibitor statics (2.5 μM, 48 h) effect on TNF-α-induced apoptosis in Th9 cells.
Stattic purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
Assess the effects of tofacitinib (10 μM, 48 h), stattics (2.5 μM, 48 h), and IL-9mAb on the cell migration of RA-FLS after treatment with the supernatant from RA-Th9 cells.
-
Cell Mol Immunol
IL-18 drives the Bhlhe40-mediated pathogenic Th17 cell response and exacerbates autoimmune disease progression. [Abstract]2025 Oct 14. PMID: 41087718 -
Nat Cell Biol
2026 Mar 13. PMID: 41826695 -
Cell Host Microbe
Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. [Abstract]2026 Feb 11;34(2):245-262.e8. PMID: 41605216 -
Cancer Res
Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. [Abstract]2024 Feb 1;84(3):479-492. PMID: 38095536 -
Nat Commun
Signaling cascades shape functional subpopulations of cortical astrocytes in male wild-type mice and APP/PS1dE9 Alzheimer's disease model. [Abstract]2026 Apr 14;17(1):4194. PMID: 41980951 -
Nat Commun
Macrophage-derived amphiregulin induces myofibroblast transition in adipogenic lineage precursors near Staphylococcus aureus abscess in bone marrow. [Abstract]2025 Sep 25;16(1):8409. PMID: 40998791 -
Nat Commun
Medium from human iPSC-derived primitive macrophages promotes adult cardiomyocyte proliferation and cardiac regeneration. [Abstract]2025 Mar 27;16(1):3012. PMID: 40148355 -
Nat Commun
Macrophage STING signaling promotes fibrosis in benign airway stenosis via an IL6-STAT3 pathway. [Abstract]2025 Jan 3;16(1):289. PMID: 39753529 -
Nat Commun
2021 Jun 15;12(1):3651. PMID: 34131122 -
Cell Death Differ
RNF220 mediates K63-linked polyubiquitination of STAT3 and aggravates pathological cardiac hypertrophy. [Abstract]2025 Nov 11. PMID: 41219491 -
Cell Death Differ
FMRP regulation of STAT3-MYC signaling is critical for adult hippocampal neurogenesis and cognitive flexibility. [Abstract]2025 Jul 19. PMID: 40683950 -
Acta Pharm Sin B
Elevated SNHG15 empowers keratinocytes hyperproliferation through activation of STAT3/Cyclin D1 axis in psoriasis. [Abstract]2025 Dec;15(12):6430-6443. PMID: 41477326 -
Acta Pharm Sin B
2025 Aug;15(8):4078-4095. PMID: 40893681 -
Acta Pharm Sin B
2025 Mar;15(3):1535-1551. PMID: 40370558 -
Acta Pharm Sin B
2025 Jan;15(1):409-423. PMID: 40041920 -
Sci Transl Med
Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. [Abstract]2021 Oct 6;13(614):eabg6428. PMID: 34613810 -
Adv Sci (Weinh)
Single-Cell RNA-Sequencing Provides Insight into Skeletal Muscle Evolution during the Selection of Muscle Characteristics. [Abstract]2023 Dec;10(35):e2305080. PMID: 37870215 -
J Clin Invest
IL20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer. [Abstract]2022 Oct 17;132(20):e157917. PMID: 36006737 -
Exp Hematol Oncol
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation. [Abstract]2024 Oct 1;13(1):97. PMID: 39354638 -
Exp Hematol Oncol
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer. [Abstract]2024 Jun 26;13(1):63. PMID: 38926796 -
Theranostics
SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1. [Abstract]2024 Oct 7;14(17):6543-6559. PMID: 39479456 -
Theranostics
Inactivating IL34 promotes regenerating muscle stem cell expansion and attenuates Duchenne muscular dystrophy in mouse models. [Abstract]2023 Apr 23;13(8):2588-2604. PMID: 37215564 -
Theranostics
OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes. [Abstract]2023 Apr 17;13(7):2263-2280. PMID: 37153745 -
J Adv Res
2025 Nov 29:S2090-1232(25)00961-0. PMID: 41325838 -
J Adv Res
Strain specificity of lactobacilli with promoted colonization by galactooligosaccharides administration in protecting intestinal barriers during Salmonella infection. [Abstract]2024 Feb:56:1-14. PMID: 36894120 -
J Adv Res
Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway. [Abstract]2023 May:47:151-162. PMID: 35842187 -
J Exp Clin Cancer Res
Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis. [Abstract]2025 Jun 5;44(1):172. PMID: 40474298 -
J Exp Clin Cancer Res
Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4+ and CD8+ T cells. [Abstract]2025 Jan 31;44(1):33. PMID: 39891284 -
J Exp Clin Cancer Res
CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. [Abstract]2024 Oct 3;43(1):277. PMID: 39358777 -
J Exp Clin Cancer Res
Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment. [Abstract]2023 Aug 11;42(1):206. PMID: 37563649 -
J Exp Clin Cancer Res
Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion. [Abstract]2021 Jan 4;40(1):4. PMID: 33390170 -
J Exp Clin Cancer Res
Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop. [Abstract]2018 Dec 20;37(1):321. PMID: 30572915 -
J Exp Clin Cancer Res
17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression. [Abstract]2018 Jul 3;37(1):133. PMID: 29970138 -
J Nanobiotechnology
Exosome-shuttled miR-5121 from A2 astrocytes promotes BSCB repair after traumatic SCI by activating autophagy in vascular endothelial cells. [Abstract]2025 Apr 15;23(1):291. PMID: 40229869 -
Sci Adv
Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3. [Abstract]2025 Jun 27;11(26):eadu8422. PMID: 40561034 -
Sci Adv
Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches. [Abstract]2022 Feb 11;8(6):eabj1262. PMID: 35148178 -
Redox Biol
Quercetin alleviates LPS/iE-DAP-induced liver injury by suppressing ferroptosis via regulating ferritinophagy and intracellular iron efflux. [Abstract]2025 Apr:81:103557. PMID: 39986118 -
Redox Biol
BNP protects against diabetic cardiomyopathy by promoting Opa1-mediated mitochondrial fusion via activating the PKG-STAT3 pathway. [Abstract]2023 Jun:62:102702. PMID: 37116257 -
Redox Biol
Paeonol promotes Opa1-mediated mitochondrial fusion via activating the CK2α-Stat3 pathway in diabetic cardiomyopathy. [Abstract]2021 Oct;46:102098. PMID: 34418601 -
Cell Rep Med
HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]2026 Apr 21;7(4):102691. PMID: 41861828 -
Cell Rep Med
STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. [Abstract]2024 Mar 19;5(3):101472. PMID: 38508140 -
J Immunother Cancer
Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma. [Abstract]2020 Mar;8(1):e000111. PMID: 32152220 -
J Immunother Cancer
Tumor-released autophagosomes induces CD4+ T cell-mediated immunosuppression via a TLR2-IL-6 cascade. [Abstract]2019 Jul 12;7(1):178. PMID: 31300052 -
J Immunother Cancer
Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. [Abstract]2018 Dec 18;6(1):151. PMID: 30563569 -
Pharmacol Res
Daphnetin ameliorates Aβ pathogenesis via STAT3/GFAP signaling in an APP/PS1 double-transgenic mouse model of Alzheimer's disease. [Abstract]2022 Jun;180:106227. PMID: 35452800 -
Pharmacol Res
Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. [Abstract]2019 Sep:147:104307. PMID: 31181334 -
Cell Mol Biol Lett
CD209a regulates metabolic dysfunction-associated steatotic liver disease development through macrophage STAT3 signaling pathway. [Abstract]2025 Nov 28;30(1):141. PMID: 41315908 -
J Neuroinflammation
IFN-γ signaling links ventriculomegaly to choroid plexus and ependyma dysfunction following maternal immune activation. [Abstract]2025 Mar 15;22(1):83. PMID: 40089736 -
J Neuroinflammation
Microglia mediate memory dysfunction via excitatory synaptic elimination in a fracture surgery mouse model. [Abstract]2024 Sep 16;21(1):227. PMID: 39285282 -
Cancer Lett
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma. [Abstract]2024 May 10:216956. PMID: 38735381 -
J Neuroinflammation
Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis. [Abstract]2022 Feb 18;19(1):52. PMID: 35180864 -
Cancer Lett
Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. [Abstract]2021 Oct 10:518:35-48. PMID: 34139285 -
Int J Biol Sci
BGN/FAP/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer. [Abstract]2023 Jan 1;19(2):465-483. PMID: 36632455 -
Cell Death Dis
Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. [Abstract]2026 Mar 27;17(1):364. PMID: 41896539 -
Cell Death Dis
Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-κB and STAT3 signaling pathways in nasopharyngeal carcinoma. [Abstract]2025 Feb 25;16(1):129. PMID: 40000620 -
Cell Death Dis
S1PR3-driven positive feedback loop sustains STAT3 activation and keratinocyte hyperproliferation in psoriasis. [Abstract]2025 Jan 20;16(1):31. PMID: 39833165 -
Cell Death Dis
Hippo kinases Mst1 and Mst2 maintain NK cell homeostasis by orchestrating metabolic state and transcriptional activity. [Abstract]2024 Jun 19;15(6):430. PMID: 38898027 -
Cell Death Dis
N6-methyladenosine modification of REG1α facilitates colorectal cancer progression via β-catenin/MYC/LDHA axis mediated glycolytic reprogramming. [Abstract]2023 Aug 25;14(8):557. PMID: 37626036 -
Cell Death Dis
Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma. [Abstract]2022 May 25;13(5):496. PMID: 35614034 -
Cell Death Dis
The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype. [Abstract]2022 Jan 10;13(1):36. PMID: 35013108 -
Cell Death Dis
Inhibition of nuclear receptor RORα attenuates cartilage damage in osteoarthritis by modulating IL-6/STAT3 pathway. [Abstract]2021 Sep 28;12(10):886. PMID: 34584074 -
Cell Death Dis
Circular RNA UBE2Q2 promotes malignant progression of gastric cancer by regulating signal transducer and activator of transcription 3-mediated autophagy and glycolysis. [Abstract]2021 Oct 5;12(10):910. PMID: 34611143 -
Cell Death Dis
CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma. [Abstract]2019 Oct 14;10(10):781. PMID: 31611552 -
Cell Death Dis
Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. [Abstract]2018 Jan 18;9(2):25. PMID: 29348540 -
-
Osteoarthritis Cartilage
CRLF1/CLCF1 heterodimer involvement in intervertebral disc degeneration via exacerbation of extracellular matrix degradation and nucleus pulposus cell senescence. [Abstract]2025 May;33(5):574-589. PMID: 39986601 -
Cell Commun Signal
T cell receptor associated transmembrane adaptor 1 (TRAT1) modulates human Th17 and Treg responses via PI3-kinase and STAT dependent mechanisms. [Abstract]2025 Oct 10;23(1):431. PMID: 41074026 -
Cell Commun Signal
Integrin αVβ1-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis. [Abstract]2024 Jun 6;22(1):313. PMID: 38844957 -
Cell Commun Signal
Activation of kappa opioid receptor suppresses post-traumatic osteoarthritis via sequestering STAT3 on the plasma membrane. [Abstract]2024 Jun 18;22(1):335. PMID: 38890746 -
Int J Biol Macromol
Carpaine alleviates NASH-related fibrosis by targeting Nid1 to inhibit IL-6/JAK/STAT3 signaling and macrophage M1 polarization. [Abstract]2025 Dec 3;337(Pt 1):149451. PMID: 41349744 -
Int J Biol Macromol
Targeting of KOR by famotidine promotes OPC maturation differentiation and CNS remyelination via STAT3 signaling pathway. [Abstract]2024 Jun;269(Pt 2):131964. PMID: 38692525 -
Acta Pharmacol Sin
Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer. [Abstract]2025 Jan;46(1):184-195. PMID: 39198663 -
Phytomedicine
Celastrol disrupts the inflammatory feedback loop driven by Tenascin-C⁺ fibroblast subtype in psoriasis: Insights from single-cell RNA sequencing and experimental validation. [Abstract]2026 Apr:153:157988. PMID: 41763138 -
Phytomedicine
Baicalin and ginsenoside Rb1 suppress the activation of cardiac fibroblasts via regulating the GRK2/AT1R/MasR network. [Abstract]2025 Oct 4:148:157371. PMID: 41110355 -
Phytomedicine
Shexiang baoxin pill ameliorates cardiac fibrosis by inhibiting fibroblast to myofibroblast transition through STAT3 phosphorylation suppression. [Abstract]2025 Sep 15:148:157263. PMID: 40975042 -
Phytomedicine
Naringenin alleviates intestinal ischemia/reperfusion injury by inhibiting ferroptosis via targeting YAP/STAT3 signaling axis. [Abstract]2024 Dec:135:156095. PMID: 39383632 -
Phytomedicine
Ophiopogonin D alleviates acute lung injury by regulating inflammation via the STAT3/A20/ASK1 axis. [Abstract]2024 Jul 25:130:155482. PMID: 38824823 -
Phytomedicine
Ailanthone inhibits non-small cell lung cancer growth and metastasis through targeting UPF1/GAS5/ULK1 signaling pathway. [Abstract]2024 Jun:128:155333. PMID: 38518633 -
Phytomedicine
Glycosides from Buyang Huanwu Decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway. [Abstract]2022 Oct:105:154385. PMID: 35987015 -
Phytomedicine
Protective effect and mechanism of loganin and morroniside on acute lung injury and pulmonary fibrosis. [Abstract]2022 May:99:154030. PMID: 35279615 -
Phytomedicine
Natural pseurotins and analogs thereof inhibit activation of B-cells and differentiation into the plasma cells. [Abstract]2020 Apr;69:153194. PMID: 32146299 -
Free Radic Biol Med
Novel therapeutic approach for psoriasis: Upregulating FcRn to inhibit ferroptosis and alleviate lesional skin. [Abstract]2024 Sep 11:S0891-5849(24)00657-9. PMID: 39270944 -
Free Radic Biol Med
IL-6/gp130/STAT3 signaling contributed to the activation of the PERK arm of the unfolded protein response in response to chronic β-adrenergic stimulation. [Abstract]2023 Aug 20:205:163-174. PMID: 37307935 -
Free Radic Biol Med
STAT3 signaling promotes cardiac injury by upregulating NCOA4-mediated ferritinophagy and ferroptosis in high-fat-diet fed mice. [Abstract]2023 May 20:201:111-125. PMID: 36940731 -
-
Am J Transplant
The NLRP3 inflammasome regulates corneal allograft rejection through enhanced phosphorylation of STAT3. [Abstract]2020 Dec;20(12):3354-3366. PMID: 32583615 -
NPJ Precis Oncol
Hepatocellular carcinoma cells downregulate PGAM2 via SIRT2-mediated deacetylation modification to enhance aerobic glycolysis. [Abstract]2025 May 16;9(1):143. PMID: 40379975 -
Br J Pharmacol
Enhanced responsiveness of platelets to vicagrel in IL-10-deficient mice through STAT3-dependent up-regulation of the hydrolase arylacetamide deacetylase in the intestine. [Abstract]2019 Jun;176(11):1717-1727. PMID: 30825385 -
JHEP Rep
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle. [Abstract]2025 Jan 20;7(5):101329. PMID: 40290518 -
Biomed Pharmacother
2025 Apr 16:187:118054. PMID: 40245547 -
J Transl Med
ITIH5-mediated fibroblast/macrophage crosstalk exacerbates cardiac remodelling after myocardial infarction. [Abstract]2025 Feb 24;23(1):224. PMID: 39994656 -
J Transl Med
Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC. [Abstract]2022 May 31;20(1):248. PMID: 35642002 -
Biomed Pharmacother
Activation of α7nAChR preserves intestinal barrier integrity by enhancing the HO-1 / STAT3 signaling to inhibit NF-κB activation in mice. [Abstract]2022 May:149:112733. PMID: 36068769 -
Cell Mol Gastroenterol Hepatol
Interleukin 22 Expands Transit-Amplifying Cells While Depleting Lgr5+ Stem Cells via Inhibition of Wnt and Notch Signaling. [Abstract]2019;7(2):255-274. PMID: 30686779 -
Stem Cell Res Ther
Modulation of senescent Lepr+ skeletal stem cells via suppression of leptin-induced STAT3‒FGF7 axis activation alleviates abnormal subchondral bone remodeling and osteoarthritis progression. [Abstract]2025 May 5;16(1):227. PMID: 40325465 -
Stem Cell Res Ther
MSC-exosomes pretreated by Danshensu extracts pretreating to target the hsa-miR-27a-5p and STAT3-SHANK2 to enhanced antifibrotic therapy. [Abstract]2025 Feb 4;16(1):40. PMID: 39901236 -
Environ Pollut
Aquatic high iron induces hepatic ferroptosis in zebrafish (Danio rerio) via interleukin-22 signaling pathway. [Abstract]2025 Jan 1:125627. PMID: 39746632 -
Stem Cell Res Ther
Targeting NPM1 inhibits proliferation and promotes apoptosis of hepatic progenitor cells via suppression of mTOR signalling pathway. [Abstract]2024 Sep 11;15(1):292. PMID: 39256792 -
Oncogene
Ezh2Y641F mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma. [Abstract]2022 Nov;41(46):4983-4993. PMID: 36220978 -
Oncogene
NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation. [Abstract]2022 Feb;41(6):907-919. PMID: 34992218 -
Aging Cell
Upregulation of the Cav1.3 channel in inner hair cells by interleukin 6-dependent inflammaging contributes to age-related hearing loss. [Abstract]2024 Aug 15:e14305. PMID: 39148148 -
Cell Death Discov
GAS6/AXL signaling promotes M2 microglia efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy. [Abstract]2025 Jun 6;11(1):268. PMID: 40480981 -
Cell Death Discov
CXCL12 alone is enough to Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts. [Abstract]2025 Apr 8;11(1):156. PMID: 40199862 -
Cell Death Discov
NCAPD3 exerts tumor-promoting effects in prostatic cancer via dual impact on miR-30a-5p by STAT3-MALAT1 and MYC. [Abstract]2024 Apr 1;10(1):159. PMID: 38561330 -
Cell Rep
Pancreatic β cell interleukin-22 receptor subunit alpha 1 deficiency impairs β cell function in type 2 diabetes via cytochrome b5 reductase 3. [Abstract]2024 Dec 13;43(12):115057. PMID: 39675006 -
Br J Cancer
Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells. [Abstract]2021 Jul;125(1):101-111. PMID: 33772151 -
Int J Nanomedicine
Chitosan-Coated-PLGA Nanoparticles Enhance the Antitumor and Antimigration Activity of Stattic - A STAT3 Dimerization Blocker. [Abstract]2022 Jan 11;17:137-150. PMID: 35046650 -
Cell Mol Life Sci
Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis. [Abstract]2025 Nov 13;82(1):396. PMID: 41231254 -
J Agric Food Chem
Molecular Mechanism of Glycation Structure-Mediated Immune Recognition and Sensitization by Typical Milk Allergens. [Abstract]2025 Aug 27;73(34):21566-21577. PMID: 40801482 -
Cell Mol Life Sci
Inhibition of DYRK1B BY C81 impedes inflammatory processes in leukocytes by reducing STAT3 activity. [Abstract]2025 Feb 22;82(1):85. PMID: 39985685 -
EMBO Rep
Chronic inflammation decreases HSC fitness by activating the druggable Jak/Stat3 signaling pathway. [Abstract]2023 Jan 9;24(1):e54729. PMID: 36341527 -
Ecotoxicol Environ Saf
Exposure to short-chain chlorinated paraffins induces astrocyte activation via JAK2/STAT3 signaling pathway. [Abstract]2022 Dec 15:248:114268. PMID: 36375367
Stattic purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2022 Dec 15:248:114268. [Abstract]
Stattic (10 μM) effectively attenuates the SCCP-mediated increase in iNOS and GFAP expression in C6 cells.
-
Mol Ther Nucleic Acids
Intestinal epithelial cell autophagy deficiency suppresses inflammation-associated colon tumorigenesis. [Abstract]2022 Feb 20:28:35-46. PMID: 35317201 -
Cancer Cell Int
PRRG4 regulates mitochondrial function and promotes migratory behaviors of breast cancer cells through the Src-STAT3-POLG axis. [Abstract]2023 Dec 16;23(1):323. PMID: 38102641 -
Cancer Cell Int
A novel STAT3/ NFκB p50 axis regulates stromal-KDM2A to promote M2 macrophage-mediated chemoresistance in breast cancer. [Abstract]2023 Oct 11;23(1):237. PMID: 37821959 -
Cancer Cell Int
SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma. [Abstract]2022 Jan 15;22(1):24. PMID: 35033067 -
-
J Mol Cell Biol
CSF2 upregulates CXCL3 expression in adipocytes to promote metastasis of breast cancer via the FAK signaling pathway. [Abstract]2023 Aug 3;15(4):mjad025. PMID: 37073091 -
Cell Biol Toxicol
2023 Aug;39(4):1835-1850. PMID: 36522543 -
Biochem Pharmacol
Celastrol synergizes with MEK1 inhibitor nedometinib to overcome resistance in bladder cancer via dual suppression of CDK1/CDC5L and feedback-activated Akt/STAT3. [Abstract]2025 Dec 10:245:117629. PMID: 41386559 -
Biochem Pharmacol
RORγt agonist LYC-55716 potentiates IFN-α's efficacy in hepatocellular carcinoma through enhancing cytotoxicity of Tc17 cells and infiltration of CD8+ T cells. [Abstract]2025 Apr 29:116963. PMID: 40312017 -
J Ginseng Res
Ginsenoside Rg1 alleviates vascular remodeling in hypoxia-induced pulmonary hypertension mice through the calpain-1/STAT3 signaling pathway. [Abstract]2024 Jul;48(4):405-416. PMID: 39036731 -
Cell Prolif
PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness. [Abstract]2023 Jan;56(1):e13337. PMID: 36127291 -
J Ethnopharmacol
Direct targeting of STAT3 by xanthatin suppresses allergic airway inflammation via inhibition of TSLP release and NK2 cell polarization. [Abstract]2026 May 10:362:121296. PMID: 41621761 -
J Ethnopharmacol
Cedrol from Platycladus orientalis (L.) Franco regulates M1/M2 polarization of macrophages and promotes hair regeneration. [Abstract]2026 Apr 24:361:121268. PMID: 41611183 -
J Ethnopharmacol
Integrated serum pharmacochemistry with network pharmacology and pharmacological validation to elucidate the mechanism of yiqitongmai decoction (YQTMD) against myocardial infarction. [Abstract]2024 May 13:118329. PMID: 38750989 -
J Ethnopharmacol
Rosmarinic acid alleviates toosendanin-induced liver injury through restoration of autophagic flux and lysosomal function by activating JAK2/STAT3/CTSC pathway. [Abstract]2024 Aug 10:330:118196. PMID: 38631488 -
Mol Ther Oncolytics
Cardamonin suppresses pro-tumor function of macrophages by decreasing M2 polarization on ovarian cancer cells via mTOR inhibition. [Abstract]2022 Jun 25;26:175-188. PMID: 35860007 -
Life Sci
Glucocorticoid reduces mortality in LPS-induced sepsis mouse model by inhibiting JAK1/STAT3-mediated inflammatory response and restoring tricarboxylic acid cycle. [Abstract]2025 May 21:375:123744. PMID: 40408938 -
Life Sci
Hinokiflavone exerts dual regulation on apoptosis and pyroptosis via the SIX4/Stat3/Akt pathway to alleviate APAP-induced liver injury. [Abstract]2024 Aug 13:122968. PMID: 39147316 -
Bone Joint Res
Repurposing the diuretic benzamil as an anti-osteosarcoma agent that acts by suppressing integrin/FAK/STAT3 signalling and compromising mitochondrial function. [Abstract]2024 Apr 4;13(4):157-168. PMID: 38569602 -
Commun Biol
Macrophages regulate vascular smooth muscle cell function during atherosclerosis progression through IL-1β/STAT3 signaling. [Abstract]2022 Dec 1;5(1):1316. PMID: 36456628 -
Mech Ageing Dev
AMPK alleviates oxidative stress‑induced premature senescence via inhibition of NF-κB/STAT3 axis-mediated positive feedback loop. [Abstract]2020 Oct;191:111347. PMID: 32882228 -
Respir Res
Exogenous IL-25 ameliorates airway neutrophilia via suppressing macrophage M1 polarization and the expression of IL-12 and IL-23 in asthma. [Abstract]2023 Oct 28;24(1):260. PMID: 37898756 -
Inflammation
2024 Feb;47(1):307-322. PMID: 37782452 -
Nutrients
Three Polymethoxyflavones Purified from Ougan ( Citrus reticulata Cv. Suavissima) Inhibited LPS-Induced NO Elevation in the Neuroglia BV-2 Cell Line via the JAK2/STAT3 Pathway. [Abstract]2019 Apr 5;11(4):791. PMID: 30959824 -
Int J Oncol
2026 May;68(5):59. PMID: 41823522 -
PLoS Pathog
Glutamine alleviates Staphylococcus aureus-induced mastitis by modulating macrophage polarisation. [Abstract]2026 Mar 11;22(3):e1014053. PMID: 41811877 -
Int J Mol Sci
STAT3 Increases CVB3 Replication and Acute Pancreatitis and Myocarditis Pathology via Impeding Nuclear Translocation of STAT1 and Interferon-Stimulated Gene Expression. [Abstract]2024 Aug 19;25(16):9007. PMID: 39201692 -
Int J Mol Sci
Threonine Deficiency Increases Triglyceride Deposition in Primary Duck Hepatocytes by Reducing STAT3 Phosphorylation. [Abstract]2024 Jul 26;25(15):8142. PMID: 39125712 -
Int J Mol Sci
Lipid-Independent Regulation of PLIN5 via IL-6 through the JAK/STAT3 Axis in Hep3B Cells. [Abstract]2023 Apr 13;24(8):7219. PMID: 37108378 -
Int J Oncol
High‑throughput screening identification of a small‑molecule compound that induces ferroptosis and attenuates the invasion and migration of hepatocellular carcinoma cells by targeting the STAT3/GPX4 axis. [Abstract]2023 Mar;62(3):42. PMID: 36825585 -
-
Biomolecules
Human Menstrual Blood-Derived Stem Cells Protect against Tacrolimus-Induced Islet Dysfunction via Cystathionine β-Synthase Mediated IL-6/STAT3 Inactivation. [Abstract]2024 Jun 8;14(6):671. PMID: 38927074 -
Front Pharmacol
Strongylocentrotus nudus Eggs Polysaccharide Enhances Macrophage Phagocytosis Against E.coli Infection by TLR4/STAT3 Axis. [Abstract]2022 Mar 17;13:807440. PMID: 35370674 -
Eur J Pharm Sci
Development and in vitro/in vivo evaluation of polymeric dissolving microneedle formulation for psoriasis treatment. [Abstract]2026 Mar 1:218:107429. PMID: 41506586 -
Int Immunopharmacol
Lactate-mediated Ran lactylation at lysine 123 promotes astrocytes polarization after oxygen-glucose deprivation/reoxygenation. [Abstract]2026 Jan 1;168(Pt 2):115861. PMID: 41275824 -
Invest Ophthalmol Vis Sci
Epac1 Inhibits Orbital Fibroblast Activation to Ameliorate Thyroid-Associated Orbitopathy-Like Features Through the JAK/STAT Signaling Pathway. [Abstract]2025 Jul 1;66(9):68. PMID: 40736178 -
Int Immunopharmacol
2025 May 6:157:114731. PMID: 40334628 -
Int Immunopharmacol
TAMs-derived SPP1, regulated by HIF-1α/STAT3 signaling pathway, influences colorectal cancer malignant progression by activation of EMT via integrin αvβ3. [Abstract]2025 May 26:159:114947. PMID: 40424660 -
Eur J Pharmacol
Carnosol inhibits influenza A virus by disrupting the viral envelope and interfering with Jak2/STAT3 signaling pathway. [Abstract]2025 Apr 9:177606. PMID: 40216182 -
Int Immunopharmacol
Aerosol inhalation of rhIL-10 improves acute lung injury in mice by affecting pulmonary neutrophil phenotypes through neutrophil-platelet aggregates. [Abstract]2025 Jan 6:147:113948. PMID: 39778276 -
Int Immunopharmacol
Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation. [Abstract]2024 Sep 27;142(Pt B):113258. PMID: 39340991 -
Int Immunopharmacol
Long noncoding RNA MCM3AP-AS1 attenuates sepsis-induced cardiomyopathy by improving inflammation, oxidative stress, and mitochondrial function through mediating the miR-501-3p/CADM1/STAT3 axis. [Abstract]2024 Feb 15:128:111500. PMID: 38237222 -
Int Immunopharmacol
IL-11 ameliorates oxidative stress damage in neurons after spinal cord injury by activating the JAK/STAT signaling pathway. [Abstract]2024 Jan 25:127:111367. PMID: 38160564 -
Am J Physiol Cell Physiol
OTUD6A in tubular epithelial cells mediates Angiotensin II-induced kidney injury by targeting STAT3. [Abstract]2024 Feb 1;326(2):C400-C413. PMID: 38105755 -
Int Immunopharmacol
STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage. [Abstract]2023 Oct:123:110709. PMID: 37515849 -
Int Immunopharmacol
ASCT2-mediated glutamine uptake of epithelial cells facilitates CCL5-induced T cell infiltration via ROS-STAT3 pathway in oral lichen planus. [Abstract]2023 Jun:119:110216. PMID: 37116342 -
Mol Cancer Res
Adipokine Apelin/APJ Pathway Promotes Peritoneal Dissemination of Ovarian Cancer Cells by Regulating Lipid Metabolism. [Abstract]2021 Sep;19(9):1534-1545. PMID: 34172534 -
Int Immunopharmacol
miR-383 reduces keratinocyte proliferation and induces the apoptosis in psoriasis via disruption of LCN2-dependent JAK/STAT pathway activation. [Abstract]2021 Jul:96:107587. PMID: 33819732 -
Int Immunopharmacol
Protective effects of iridoid glycosides on acute colitis via inhibition of the inflammatory response mediated by the STAT3/NF-кB pathway. [Abstract]2020 Apr;81:106240. PMID: 32044657 -
Mol Cancer Res
2019 Jun;17(6):1378-1390. PMID: 30858172 -
Toxicology
Co-exposure to polystyrene nanoplastics and cadmium induces apoptosis in intestinal cells: Role of the IP3R/Ca²⁺/STAT3 signaling pathway. [Abstract]2026 Jun:523:154449. PMID: 41833704 -
Cancer Biol Ther
Targeting crosstalk of STAT3 between tumor-associated M2 macrophages and Tregs in colorectal cancer. [Abstract]2023 Dec 31;24(1):2226418. PMID: 37381162 -
Neuropharmacology
PirB negatively regulates the inflammatory activation of astrocytes in a mouse model of sleep deprivation. [Abstract]2023 Sep 1:235:109571. PMID: 37146940 -
J Mol Biol
Cancer-associated adipocyte-derived G-CSF promotes breast cancer malignancy via Stat3 signaling. [Abstract]2020 Sep 1;12(9):723-737. PMID: 32242230 -
Cancers (Basel)
LncRNA HAR1A Suppresses the Development of Non-Small Cell Lung Cancer by Inactivating the STAT3 Pathway. [Abstract]2022 Jun 8;14(12):2845. PMID: 35740511 -
-
Mediators Inflamm
LncRNA NEAT1 Knockdown Alleviates Macrophage Ferroptosis and Atherosclerosis by Suppressing STAT3 Activation. [Abstract]2025 Nov 12:2025:8862449. PMID: 41268533 -
J Mol Med (Berl)
BMSCs-derived exosomal AKAP12 alleviates neuronal cell ferroptosis by inhibiting the STAT3 and ERK signaling pathways in spinal cord injury. [Abstract]2025 Oct 15. PMID: 41094204 -
FASEB J
Brown adipose tissue-derived exosomes improve polycystic ovary syndrome in mice via STAT3/GPX4 signaling pathway. [Abstract]2024 Sep 30;38(18):e70062. PMID: 39305125 -
Biochim Biophys Acta Mol Basis Dis
Involvement of PD-1+CD4+ T cells in the development of traumatic tracheal stenosis by regulating the IL-17/STAT3 pathway. [Abstract]2024 Aug;1870(6):167216. PMID: 38718843 -
J Cell Mol Med
Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4. [Abstract]2022 Apr;26(8):2363-2376. PMID: 35224833 -
J Cell Mol Med
Long non-coding RNA MALAT1 regulates angiogenesis following oxygen-glucose deprivation/reoxygenation. [Abstract]2019 Apr;23(4):2970-2983. PMID: 30784209 -
Oncol Res
SDHA Deficiency in Hepatocellular Carcinoma Promotes Tumor Progression through Succinate-Induced M2 Macrophage Polarization. [Abstract]2026 Jan 19;34(2):25. PMID: 41613800 -
J Inflamm Res
SMP30 Attenuates Lens Epithelial Cells Pyroptosis of Cataract via the Downregulation of p-STAT3. [Abstract]2025 Sep 8:18:12361-12377. PMID: 40951443 -
J Inflamm (Lond)
RhIL-11 reverses liver damage in septic mice by STAT3-mediated M-MDSCs induction modulated by a parallel mTORC1 signaling branch. [Abstract]2025 Jun 11;22(1):21. PMID: 40500712 -
Oncol Res
IL-17 induces NSCLC cell migration and invasion by elevating MMP19 gene transcription and expression through the interaction of p300-dependent STAT3-K631 acetylation and its Y705-phosphorylation. [Abstract]2024 Mar 20;32(4):625-641. PMID: 38560562 -
iScience
PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer. [Abstract]2024 Feb 9;27(3):109160. PMID: 38414861 -
J Inflamm Res
Tfh Exosomes Derived from Allergic Rhinitis Promote DC Maturation Through miR-142-5p/CDK5/STAT3 Pathway. [Abstract]2022 May 31:15:3187-3205. PMID: 35668915 -
Am J Physiol Heart Circ Physiol
Cytokine receptor gp130 promotes postnatal proliferation of cardiomyocytes required for the normal functional development of the heart. [Abstract]2022 Jul 1;323(1):H103-H120. PMID: 35594067 -
-
Antiviral Res
Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response. [Abstract]2023 Sep:217:105676. PMID: 37481038 -
Sci Rep
IL6/STAT3 induced GRWD1 mediates aerobic glycolysis via P53/GLUT1 signal axis in colon carcinoma. [Abstract]2025 Sep 29;15(1):33534. PMID: 41022893 -
Sci Rep
Mitochondrial-dependent apoptosis and STAT3 activation induced by oxidative stress in pemphigus vulgaris. [Abstract]2025 Aug 14;15(1):29900. PMID: 40813461 -
Sci Rep
2025 Jul 1;15(1):21259. PMID: 40596220 -
Sci Rep
Molybdenum facilitates PDLSC-based bone regeneration through the JAK/STAT3 signaling pathway. [Abstract]2025 Jul 1;15(1):22204. PMID: 40594624 -
J Biol Chem
2024 Jun 27:107499. PMID: 38944125 -
Biomedicines
KDF1 Promoted Proliferation, Migration and Invasion of Lung Adenocarcinoma Cells through Activating STAT3 and AKT Pathway. [Abstract]2023 Dec 1;11(12):3194. PMID: 38137415 -
Oncol Rep
JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type. [Abstract]2019 Jun;41(6):3219-3232. PMID: 31002364 -
Cell Signal
2025 May 17:111877. PMID: 40389045 -
Cell Signal
ANXA2 promotes chondrocyte differentiation and fracture healing by regulating the phosphorylation of STAT3 and PI3K/AKT signaling pathways. [Abstract]2025 Jan 23:127:111617. PMID: 39863030 -
ACS Pharmacol Transl Sci
Bruceine B Displays Potent Antimyeloma Activity by Inducing the Degradation of the Transcription Factor c-Maf. [Abstract]2023 Dec 5;7(1):176-185. PMID: 38230274 -
Cell Signal
STAT1/3 signaling suppresses axon degeneration and neuronal cell death through regulation of NAD+-biosynthetic and consuming enzymes. [Abstract]2023 Aug:108:110717. PMID: 37187216 -
Cytokine
Qinling liquid ameliorates renal immune inflammatory damage via activating autophagy through AMPK/Stat3 pathway in uric acid nephropathy. [Abstract]2023 Mar:163:156120. PMID: 36630870 -
Cell Signal
NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and MALAT1 through STAT3 and E2F1. [Abstract]2022 Apr:92:110265. PMID: 35085770 -
Cell Signal
2019 Mar:55:65-72. PMID: 30610893
Stattic purchased from MedChemExpress. Usage Cited in: Cell Signal. 2019 Mar:55:65-72. [Abstract]
Western blotting and densitometric analysis of p-STAT3 in Lo2 cells after 24 h of treatment with the indicated concentrations of the STAT3 inhibitor stattic.
-
World J Stem Cells
Effects of miR-214-5p and miR-21-5p in hypoxic endometrial epithelial-cell-derived exosomes on human umbilical cord mesenchymal stem cells. [Abstract]2024 Nov 26;16(11):906-925. PMID: 39619875 -
Clin Exp Med
Bioinformatics and experimental approaches identify NME8 as a promoter of the metastasis of renal cell carcinoma by activating the JAK/STAT signaling pathway. [Abstract]2026 Jan 2;26(1):68. PMID: 41483244 -
Vet Res
Th17 cells/IL-17A shape Pasteurella multocida serotype A infection in murine and rabbit models. [Abstract]2025 Dec 16;56(1):229. PMID: 41402924 -
-
Metab Brain Dis
Mechanistic study of butylphthalide in alleviating cerebral Edema after intracerebral Hemorrhage by regulating miR-7-5p expression. [Abstract]2025 Jul 1;40(6):238. PMID: 40591076 -
Mol Med Rep
Stattic suppresses p‑STAT3 and induces cell death in T‑cell acute lymphoblastic leukemia. [Abstract]2025 Feb;31(2):51. PMID: 39670305 -
Vet Res
Binding of Trichinella spiralis C-type lectin with syndecan-1 on intestinal epithelial cells mediates larval invasion of intestinal epithelium. [Abstract]2023 Oct 2;54(1):86. PMID: 37784173 -
Vascul Pharmacol
Therapeutic potential and protective role of GRK6 overexpression in pulmonary arterial hypertension. [Abstract]2023 Dec:153:107233. PMID: 37742818 -
Exp Cell Res
Colorectal cancer-derived extracellular vesicles containing HSP70 enhance macrophage phagocytosis by up-regulating MARCO expression. [Abstract]2023 Mar 22;426(2):113565. PMID: 36958650 -
Mol Med Rep
STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells. [Abstract]2023 Apr;27(4):81. PMID: 36825563
Stattic purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Apr;27(4):81. [Abstract]
Stattic (5, 15, 30 µM; 4 h) markedly inhibits Y705 STAT3 phosphorylation in both senescent TC‑1 (Fig. C) and TRAMP‑C2 (Fig. D) cells in a concentration‑dependent manner.
-
Parasit Vectors
B7-H4 reduction induced by Toxoplasma gondii infection results in dysfunction of decidual dendritic cells by regulating the JAK2/STAT3 pathway. [Abstract]2022 May 3;15(1):157. PMID: 35505420 -
Front Physiol
Endoplasmic Reticulum Stress/Ca2+-Calmodulin-Dependent Protein Kinase/Signal Transducer and Activator of Transcription 3 Pathway Plays a Role in the Regulation of Cellular Zinc Deficiency in Myocardial Ischemia/Reperfusion Injury. [Abstract]2022 Jan 5:12:736920. PMID: 35069232 -
Front Physiol
High Glucose Activated Cardiac Fibroblasts by a Disruption of Mitochondria-Associated Membranes. [Abstract]2021 Aug 18;12:724470. PMID: 34483973 -
Front Oncol
Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway. [Abstract]2021 Nov 22;11:762523. PMID: 34881181 -
J Cancer
STAT3 inhibitor Stattic Exhibits the Synergistic Effect with FGFRs Inhibitor Erdafitinib in FGFR1-positive Lung Squamous Cell Carcinoma. [Abstract]2024 Aug 19;15(16):5415-5424. PMID: 39247610 -
Mol Carcinog
The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. [Abstract]2024 Sep;63(9):1738-1749. PMID: 38837427 -
J Cancer
Upregulation of V-ATPase by STAT3 Activation Promotes Anoikis Resistance and Tumor Metastasis. [Abstract]2021 Jun 11;12(16):4819-4829. PMID: 34234852 -
J Cancer
Activated STAT3 Could Reduce Survival in Patients with Esophageal Squamous Cell Carcinoma by Up-regulating VEGF and Cyclin D1 Expression. [Abstract]2020 Jan 20;11(7):1859-1868. PMID: 32194797 -
IUBMB Life
MicroRNA-204 deregulation in lung adenocarcinoma controls the biological behaviors of endothelial cells potentially by modulating Janus kinase 2-signal transducer and activator of transcription 3 pathway. [Abstract]2018 Jan;70(1):81-91. PMID: 29281186
Stattic purchased from MedChemExpress. Usage Cited in: IUBMB Life. 2018 Jan;70(1):81-91. [Abstract]
A549 cells are treated with TG101348 (3 nM), BMS-911543 (1.5 nM), and Stattic (2.5 lM) for 24 h, and the conditioned media are collected and applied for tube formation assay in HUVECs.
-
Mol Carcinog
CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. [Abstract]2017 Nov;56(11):2434-2445. PMID: 28618089
Stattic purchased from MedChemExpress. Usage Cited in: Mol Carcinog. 2017 Nov;56(11):2434-2445. [Abstract]
Cells are treated with the STAT3 inhibitor Stattic. The inhibitory action of Stattic on STAT3 phosphorylation is confirmed by Western blot.
-
Naunyn Schmiedebergs Arch Pharmacol
Corynoline promotes apoptosis and inhibits proliferation of glioblastoma via regulating the STAT3/Bcl-2 signalling pathway. [Abstract]2025 Dec 11. PMID: 41379317 -
Immunol Res
Immunomodulatory activity of 4-(Benzyloxy)phenol facilitates intracellular mycobacterial clearance through p53 mediated IL-35 signaling dependent JAK1/STAT3 pathway in human macrophages. [Abstract]2025 Jun 26;73(1):99. PMID: 40571857 -
Immunol Res
Metformin suppresses gammadelta T17 cell differentiation alleviating DSS-induced colitis. [Abstract]2025 Feb 11;73(1):49. PMID: 39934569 -
Biochim Biophys Acta Gene Regul Mech
2019 Aug;1862(8):796-806. PMID: 31295563 -
Med Microbiol Immunol
Furamidine enhances IL-23-mediated autophagic response through IL-23R-TYK2-STAT3-dependent regulation of intracellular Ca²⁺ level to facilitate mycobacterial clearance in human macrophages. [Abstract]2025 Nov 14;214(1):50. PMID: 41236630 -
Mol Immunol
Cigarette smoke-exposed microparticles released from T lymphocytes contribute to autophagy and apoptosis dysfunction in pulmonary microvascular endothelial cells. [Abstract]2025 May:181:9-17. PMID: 40048930 -
Arch Biochem Biophys
The LINC00319 binding to STAT3 promotes the cell proliferation, migration, invasion and EMT process in oral squamous cell carcinoma. [Abstract]2024 Nov:761:110170. PMID: 39366629 -
Int J Hyperthermia
Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and PD-L1 expression in human gastric cancer cells. [Abstract]2024 Feb 13;41(1):2310017. PMID: 38350654 -
J Bioenerg Biomembr
Blockage of PHLPP1 protects against myocardial ischemia/reperfusion injury in diabetic mice via activation of STAT3 signaling. [Abstract]2023 Oct;55(5):325-339. PMID: 37584737 -
Toxicol Lett
Comparative transcriptomic analysis reveals STAT3 as a candidate gene involved in aristolochic acid I-induced hepatorenal toxicity. [Abstract]2025 Dec 30:416:111811. PMID: 41478365 -
Discov Oncol
Research on the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia. [Abstract]2025 May 12;16(1):739. PMID: 40353923 -
Discov Oncol
Increased protein expression of interleukin-10 and its signalling molecules in colon cancer progression: potential prognostic and therapeutic targets. [Abstract]2025 Apr 29;16(1):637. PMID: 40299210 -
Toxicol Lett
Toosendanin induces hepatotoxicity by restraining autophagy and lysosomal function through inhibiting STAT3/CTSC axis. [Abstract]2024 Apr:394:102-113. PMID: 38460807 -
Immunol Lett
Lenvatinib-resistant liver cancer-derived HSP90α-containing extracellular vesicles enhance drug resistance via macrophage CXCL8 secretion. [Abstract]2026 Apr:278:107122. PMID: 41349809 -
Brain Sci
Minocycline Ameliorates Staphylococcus aureus-Induced Neuroinflammation and Anxiety-like Behaviors by Regulating the TLR2 and STAT3 Pathways in Microglia. [Abstract]2025 Jan 28;15(2):128. PMID: 40002461 -
Int J Biochem Cell Biol
2025 Feb 1:180:106750. PMID: 39900236 -
Vet Microbiol
2025 Dec:311:110733. PMID: 41106189 -
Int J Immunopathol Pharmacol
Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway. [Abstract]2024 Jan-Dec:38:3946320241249445. PMID: 38679570 -
DNA Cell Biol
JMJD3 Promotes Porphyromonas gingivalis Lipopolysaccharide-Induced Th17-Cell Differentiation by Modulating the STAT3-RORc Signaling Pathway. [Abstract]2022 Aug;41(8):778-787. PMID: 35867069 -
Cancer Manag Res
Normal Basal Epithelial Cells Stimulate the Migration and Invasion of Prostate Cancer Cell RM-1 by TGF-β1/STAT3 Axis in vitro. [Abstract]2021 May 7:13:3685-3697. PMID: 33994809 -
Tissue Cell
Fusobacterium nucleatum promotes bladder cancer progression and immune escape by activating the IL22/STAT3/PD-L1 signaling cascade. [Abstract]2025 Jul 29:97:103065. PMID: 40795596 -
Theriogenology
2024 Mar 1:216:118-126. PMID: 38171198 -
Gene
LncRNA GAS5 regulates apoptosis in ovarian cancer cells by regulating O-GlcNAcylation of GOLGA8B. [Abstract]2026 May 15:991:150084. PMID: 41791436 -
J Chin Med Assoc
2025 Jul 22. PMID: 40693722 -
Dev Comp Immunol
IL-21 signaling promotes IgM+ B cell proliferation and antibody production via JAK/STAT3 and AKT pathways in early vertebrates. [Abstract]2025 Jan 25:105325. PMID: 39870186 -
Odontology
Transcriptional regulation of human follicular dendritic cell-secreted protein gene by interleukin-6. [Abstract]2025 Jul;113(3):1081-1091. PMID: 39776305 -
J Oral Biosci
2025 Dec;67(4):100707. PMID: 41274690 -
Immunobiology
Ureaplasma urealyticum GrpE protein elicits glycolysis-mediated inflammatory responses through TLR2 in macrophages. [Abstract]2025 Apr 21;230(3):152902. PMID: 40273504 -
Eur J Haematol
Interferon gamma regulates a complex pro-survival signal network in chronic lymphocytic leukemia. [Abstract]2023 Apr;110(4):435-443. PMID: 36576398 -
Immunobiology
Interleukin-1beta triggers the expansion of circulating granulocytic myeloid-derived suppressor cell subset dependent on Erk1/2 activation. [Abstract]2022 Jan;227(1):152165. PMID: 34936966 -
Exp Ther Med
IL-22/IL-22R1 promotes proliferation and collagen synthesis of MRC-5 cells via the JAK/STAT3 signaling pathway and regulates airway subepithelial fibrosis. [Abstract]2020 Sep;20(3):2148-2156. PMID: 32765690 -
Exp Ther Med
Crocin has pharmacological effects against the pathological behavior of colon cancer cells by interacting with the STAT3 signaling pathway. [Abstract]2020 Feb;19(2):1297-1303. PMID: 32010302 -
Leuk Lymphoma
IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. [Abstract]2023 Jan;64(1):71-78. PMID: 36222521 -
Biochem Biophys Res Commun
Increased hepcidin in hemorrhagic plaques correlates with iron-stimulated IL-6/STAT3 pathway activation in macrophages. [Abstract]2019 Jul 23;515(2):394-400. PMID: 31153641 -
FASEB Bioadv
2025 Jan 7;7(2):e1488. PMID: 39917394 -
Int J Rheum Dis
JAK2 inhibitors improve RA combined with pulmonary fibrosis in rats by downregulating SMAD3 phosphorylation. [Abstract]2024 May;27(5):e15164. PMID: 38706209 -
In Vitro Cell Dev Biol Anim
Lactiplantibacillus plantarum promotes lactoferrin synthesis and secretion in bovine mammary epithelial cells through STAT3 and AP-1 transcription factor pathways. [Abstract]2025 Aug;61(7):886-897. PMID: 40802133 -
Curr Med Sci
Crosstalk Between Th17 Cells and Renal Tubular Epithelial Cells Promotes Fibrotic Progression in IgA Nephropathy. [Abstract]2025 Jun;45(3):626-639. PMID: 40498423 -
Turk J Haematol
The IRF2-INPP4B pathway is activated in CD4+ T cells and aggravates acute myeloid leukemia development by inhibiting apoptosis. [Abstract]2025 May 22;42(2):82-91. PMID: 39960210 -
-
-
-
-
-
-
-
-
-
-
Oxid Med Cell Longev
IL-22 Protects against Biliary Ischemia-Reperfusion Injury after Liver Transplantation via Activating STAT3 and Reducing Apoptosis and Oxidative Stress Levels In Vitro and In Vivo. [Abstract]2022 May 10;2022:9635075. PMID: 35592531 -
Comput Intell Neurosci
RAGE Regulating Vascular Remodeling in Diabetes by Regulating Mitochondrial Dynamics with JAK2/STAT3 Pathway. [Abstract]2022 Apr 22;2022:2685648. PMID: 35498181 -
Int J Biol Sci
Cancer-associated adipocytes promote the invasion and metastasis in breast cancer through LIF/CXCLs positive feedback loop. [Abstract]2022 Jan 16;18(4):1363-1380. PMID: 35280694 -
-
-
Ann Transl Med
Lower androgen levels promote abnormal cartilage development in female patients with adolescent idiopathic scoliosis. [Abstract]2021 May;9(9):784. PMID: 34268397 -
-
-
-
Solvant et solubilité
DMSO : 50 mg/mL (236.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 1.67 mg/mL (7.91 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lin L, et al. STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. Int J Oncol. 2016 Oct 12. [Content Brief]
[2]. John S McMurray, et al. A new small-molecule Stat3 inhibitor. Chem Biol. 2006 Nov;13(11):1123-4. [Content Brief]
[3]. Tsubasa Yokota, et al. STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model. Nephrol Dial Transplant. 2018 Feb 1;33(2):214-223. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.7351 mL | 23.6754 mL | 47.3507 mL | 118.3768 mL |
| 5 mM | 0.9470 mL | 4.7351 mL | 9.4701 mL | 23.6754 mL | |
| 10 mM | 0.4735 mL | 2.3675 mL | 4.7351 mL | 11.8377 mL | |
| 15 mM | 0.3157 mL | 1.5784 mL | 3.1567 mL | 7.8918 mL | |
| 20 mM | 0.2368 mL | 1.1838 mL | 2.3675 mL | 5.9188 mL | |
| 25 mM | 0.1894 mL | 0.9470 mL | 1.8940 mL | 4.7351 mL | |
| 30 mM | 0.1578 mL | 0.7892 mL | 1.5784 mL | 3.9459 mL | |
| 40 mM | 0.1184 mL | 0.5919 mL | 1.1838 mL | 2.9594 mL | |
| 50 mM | 0.0947 mL | 0.4735 mL | 0.9470 mL | 2.3675 mL | |
| 60 mM | 0.0789 mL | 0.3946 mL | 0.7892 mL | 1.9729 mL | |
| 80 mM | 0.0592 mL | 0.2959 mL | 0.5919 mL | 1.4797 mL | |
| 100 mM | 0.0474 mL | 0.2368 mL | 0.4735 mL | 1.1838 mL |